Clinical trials: Locally Advanced/Metastatic Solid Tumors
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced/Metastatic Solid Tumors
Study of ESG406 in Adults With Solid Tumors
This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration…
- Trial name
- NCT06979674
- Testing
- ESG406
- Where
- 3 sites in China
- Volunteers
- 556 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Locally Advanced and Metastatic Solid Tumors
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217…
- Trial name
- NCT04047862
- Testing
- Ociperlimab, Tislelizumab, Pemetrexed
- Where
- 65 sites in United States, Australia and 4 more
- Volunteers
- 446 people
- Sponsor
- BeiGene
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors
The primary goal of this Phase 1 study is to characterize the safety and tolerability of INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on either every two week or every four week schedules…
- Trial name
- NCT03059823
- Testing
- retifanlimab
- Where
- 80 sites in United States, Australia and 14 more
- Volunteers
- 325 people
- Sponsor
- Incyte Corporation
Locally Advanced/Metastatic HER2 Positive Solid Tumors
A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors.
- Trial name
- NCT04257110
- Testing
- BB-1701
- Where
- 12 sites in United States, China
- Volunteers
- 117 people
- Sponsor
- Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Metastatic or Locally Advanced Solid Tumors
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT05028556
- Testing
- Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
ACE2016 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment of Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor…
- Trial name
- NCT06415487
- Testing
- Cyclophosphamide, Fludarabine, ACE2016
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 30 people
- Sponsor
- Acepodia Biotech, Inc.
Solid Cancers, Solid Tumor Cancer
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or…
- Conditions
- Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Trial name
- NCT06630247
- Testing
- XL495, ADC cytotoxic agents
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Exelixis
Locally Advanced or Metastatic Solid Tumors
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
This study is an open-label, multicenter, dose-escalation, and extended-enrollment nonrandomized phase I study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of BL-M05D1 in…
- Trial name
- NCT06349811
- Testing
- BL-M05D1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT05205109
- Testing
- ATG-037, KEYTRUDA ®( Pembrolizumab)
- Where
- 7 sites in Australia, China
- Volunteers
- 98 people
- Sponsor
- Antengene Therapeutics Limited
Locally Advanced or Metastatic Solid Tumors
IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients
This is a multicenter, open-label, Phase Ib/II clinical trial to evaluate the safety, tolerability, and antitumor efficacy of IN10018 in combination with pegylated liposomal doxorubicin (PLD) or IN10018 in combination with PLD…
- Trial name
- NCT05830539
- Testing
- IN10018+PLD, IN10018+PLD+Toripalimab
- Where
- 7 sites in China
- Volunteers
- 68 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Locally Advanced (Unresectable) or Metastatic Solid Tumors
A Study of TXN10128 in Subjects With Solid Tumors
This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128.
- Trial name
- NCT05978492
- Testing
- TXN10128, Irinotecan, Paclitaxel
- Where
- 6 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Txinno Bioscience Inc.
Non-Small Cell Lung Cancer, Pancreatic Cancer
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Cancer, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT05919537
- Testing
- HMBD-001, Docetaxel, Nab-paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 68 people
- Sponsor
- Hummingbird Bioscience
Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer
A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors
1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies
- Conditions
- Locally Advanced or Metastatic Solid Carcinomas, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02990481
- Testing
- TRK-950
- Where
- 3 sites in United States, France
- Volunteers
- 38 people
- Sponsor
- Toray Industries, Inc
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies
This is a multi-regional, multi center, open label, first in human (FIH), dose-escalation, and dose-expansion study of AP203 to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
- Trial name
- APT-CUBE (NCT05473156)
- Testing
- AP203
- Where
- Taiwan
- Volunteers
- 168 people
- Sponsor
- AP Biosciences Inc.
Locally Advanced Unresectable or Metastatic Solid Tumors
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
This is a Phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, and DLTs to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD), and the RP2D of sequential doses of…
- Trial name
- NCT05636215
- Testing
- IBI354
- Where
- 6 sites in Australia, China
- Volunteers
- 368 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Locally Advanced or Metastatic Solid Tumors
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single…
- Trial name
- NCT06293651
- Testing
- DA-4505, DA-4505 + Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Dong-A ST Co., Ltd.
Unresectable, Locally Advanced or Metastatic Solid Tumors
Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety and tolerability of IBI3005 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3005.
- Trial name
- NCT06418061
- Testing
- IBI3005
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
CLDN6-positive Solid Tumor, Ovarian Cancer
A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors
Before a treatment can be approved for use, clinical studies need to be done. This study is for people with certain types of cancer that have become worse and are difficult to treat.
- Conditions
- CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT06681870
- Testing
- ASP1893
- Sponsor
- Astellas Pharma Global Development, Inc.